Study guide

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions

Key Takeaways Explain This Topic AI

Intranasal corticosteroids are the most effective single treatment for allergic rhinitis; second-generation antihistamines help itch and sneezing but not congestion.

Topical nasal decongestants are limited to 3 to 5 days to avoid rhinitis medicamentosa, and non-prescription cough and cold products are not for children under 6.

Oseltamivir works best within 48 hours but is still recommended later for high-risk or worsening patients; zanamivir is avoided in asthma.

Bacterial conjunctivitis drops are used at least four times daily; eye pain, light sensitivity, reduced vision or a red painful eye in a contact lens wearer needs urgent referral.

Otitis externa is treated with topical drops, avoiding ototoxic aminoglycosides if the eardrum may be perforated; cotton swabs should never be used in the ear canal.

Last updated: October 2026

Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions

Self-care and minor-ailment assessments are among the most common pharmacist interactions in Canada. Several provinces also allow pharmacists to prescribe for these conditions (section 2.2). The exam tests three things: choosing the most effective, safest option; knowing the product limits (age, duration, contraindications); and recognizing red flags that need referral.

1. Allergic Rhinitis

Intranasal corticosteroids (INCS) (fluticasone, mometasone, budesonide, triamcinolone, ciclesonide) are the most effective single therapy . They relieve congestion, rhinorrhea, sneezing and itch, and also improve eye symptoms.

Benefit begins within a day but peaks after 1 to 2 weeks of regular use. For seasonal allergies, start before the season.

Technique: shake, look slightly down, aim the spray away from the septum (right hand to the left nostril and vice versa), and sniff gently. This reduces nosebleeds.

Second-generation oral antihistamines (cetirizine, loratadine, desloratadine, fexofenadine, bilastine, rupatadine) help sneezing, itch and rhinorrhea but do little for congestion. Cetirizine causes the most sedation of the group.

Avoid first-generation antihistamines (diphenhydramine, chlorpheniramine): sedation, impaired driving, and anticholinergic effects in older adults.

Topical decongestants (xylometazoline, oxymetazoline) are limited to 3 to 5 days to prevent rhinitis medicamentosa (rebound congestion).

Oral decongestants: pseudoephedrine raises blood pressure and heart rate. Caution or avoid it with uncontrolled hypertension, coronary disease, hyperthyroidism, BPH with retention, angle-closure glaucoma, and MAO inhibitors. Oral phenylephrine is poorly absorbed and of doubtful benefit.

Other options: saline irrigation; ipratropium nasal spray for watery rhinorrhea; and allergen immunotherapy (subcutaneous, or sublingual tablets for grass, ragweed and house dust mite) for patients who are not controlled.

Pregnancy: saline, budesonide or fluticasone INCS, and loratadine or cetirizine are commonly recommended.

2. The Common Cold and Cough

Colds are viral, last 7 to 10 days, and do not respond to antibiotics. Supportive care: fluids, rest, saline drops or spray, humidified air, and acetaminophen or ibuprofen for fever and aches.

Honey (for children over 1 year) modestly reduces night-time cough. Never give honey to infants under 1 year (botulism).

Non-prescription cough and cold products:

Children: not for children under 6 years (Health Canada labelling).

Dextromethorphan: a serotonergic and abuse risk with MAO inhibitors and at high doses.

Codeine-containing products: Schedule II, and avoided in children under 12.

Refer the patient with:

  • shortness of breath, chest pain, wheeze or hemoptysis;
  • fever above about 39°C or fever lasting more than 3 days;
  • symptoms lasting longer than 10 to 14 days, or worsening after initial improvement;
  • a cough lasting longer than 3 weeks ;

a patient who is immunocompromised or frail.

3. Influenza

Vaccination: annual vaccination for everyone 6 months and older is the main prevention (section 16.1).

Antiviral treatment (oseltamivir 75 mg twice daily for 5 days) works best within 48 hours . It is still recommended beyond 48 hours for patients who are at high risk (for example, with asthma, chronic heart or lung disease, pregnancy, or age 65 and older), hospitalized, or worsening. PEBC sample items choose oseltamivir for a patient with asthma who is worsening 72 hours after onset.

Inhaled zanamivir can cause bronchospasm and is avoided in asthma and COPD. Amantadine is not used because of resistance.

Renal dosing: reduce the oseltamivir dose when CrCl is below 60 mL/min.

4. Eye Conditions

Condition Typical features Self-care or treatment

Bacterial conjunctivitis Purulent discharge, eyelids stuck together in the morning Often self-limited. Polymyxin B/gramicidin drops (Schedule III), 1 to 2 drops at least four times daily for 7 days. Refer if not improving after 2 to 3 days

Viral conjunctivitis Watery discharge, often after a cold; swollen preauricular node; very contagious Cold compresses, artificial tears, strict hand hygiene

Allergic conjunctivitis Itching , bilateral, watery, with allergy history Avoid allergens, cold compresses, artificial tears; ophthalmic antihistamine/mast-cell stabilizers (ketotifen, olopatadine) by prescription; naphazoline/pheniramine for 3 days or less (rebound redness)

Dry eye Gritty, burning; worse with screens or in dry air Artificial tears; preservative-free if used more than about 4 times a day; review anticholinergic drugs

Warning

Refer eye complaints with:

  • pain, light sensitivity, or reduced or blurred vision ;
  • a contact lens wearer with a red, painful eye (risk of Pseudomonas keratitis);
  • trauma or a chemical splash (irrigate first);
  • suspected herpes infection;
  • a newborn;
  • a fixed or irregular pupil;

failure to improve within 2 to 3 days.

Contact lenses are removed until the eye is clear and treatment has finished.

5. Ear Conditions

Acute otitis externa ("swimmer's ear"): ear canal pain that worsens when the tragus or pinna is pulled , itch and discharge. It is treated with topical drops (antibiotic with or without a corticosteroid, such as ciprofloxacin/dexamethasone, or acidifying drops). Oral antibiotics are not needed unless infection spreads beyond the canal.

If the eardrum may be perforated (or the patient has ear tubes), avoid potentially ototoxic drops such as neomycin or aminoglycoside-containing products. Use fluoroquinolone drops.

Prevention: dry the ears after swimming; acetic acid or alcohol-based drying drops for people prone to recurrence.

Earwax (cerumen) impaction: softening drops (carbamide peroxide, or olive or mineral oil) for several days, then gentle irrigation if appropriate. Never use cotton swabs in the canal. Refer when there is pain, discharge, hearing loss, dizziness, a perforation history or ear tubes.

Acute otitis media in children is assessed by a prescriber (section 11.1).